Home › Trial NCT07807722
Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC
- Trial IDNCT07807722
- StatusNot Yet Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorHubei Cancer Hospital
- Enrollment29
- Start date2026-09-21
- ConditionsNSCLC (Non-small Cell Lung Cancer) · EGFR · Neoadjuvant Therapy
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.